Drug intelligence / Profile preview

XZ120

Development stage: Phase 1
Lead developer: Shandong New Time Pharmaceutical
Modality: Small Molecules
Administration: Intravenous

Overview

XZ120 is an investigational small molecule drug currently in Phase 1 clinical trials for the treatment of malignant tumors, including advanced breast cancer and diffuse large B-cell lymphoma. The drug is administered intravenously and is being developed to evaluate its safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with various neoplasms. The mechanism of action for XZ120 has not been disclosed as of now. The developer and sponsor for the clinical studies is Shandong New Time Pharmaceutical.

Beyond the preview

Go deeper on XZ120.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XZ120.

Explore the full profile